{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:20:09Z","timestamp":1780392009282,"version":"3.54.1"},"reference-count":62,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research United Kingdom (CRUK)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jnci\/djz071","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T19:11:42Z","timestamp":1556824302000},"source":"Crossref","is-referenced-by-count":56,"title":["Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"},{"name":"Cancer Research UK & UCL Cancer Centre, University College of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S","family":"Wasan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Imperial College Healthcare, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Hubner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2272-3678","authenticated-orcid":false,"given":"Mair\u00e9ad G","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-7337","authenticated-orcid":false,"given":"Andre","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Manoharan","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Clatterbridge Cancer Centre, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bridgewater","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, UCL Cancer Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"issue":"7","key":"2019062108001609200_djz071-B1","doi-asserted-by":"crossref","first-page":"vii345","DOI":"10.1093\/annonc\/mdq420","article-title":"Advances in the treatment of metastatic or unresectable biliary tract cancer","volume":"21","author":"Valle","year":"2010","journal-title":"Ann Oncol"},{"key":"2019062108001609200_djz071-B2","volume-title":"AJCC Cancer Staging Manual","year":"2010"},{"issue":"4","key":"2019062108001609200_djz071-B3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ctrv.2008.11.009","article-title":"Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions","volume":"35","author":"Anderson","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"2019062108001609200_djz071-B4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"6","key":"2019062108001609200_djz071-B5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"issue":"6","key":"2019062108001609200_djz071-B6","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mds652","article-title":"A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe","volume":"24","author":"Bertuccio","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"2019062108001609200_djz071-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2019062108001609200_djz071-B8","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"2019062108001609200_djz071-B9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"issue":"14","key":"2019062108001609200_djz071-B10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"2019062108001609200_djz071-B11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"issue":"9","key":"2019062108001609200_djz071-B12","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/bjc.2016.64","article-title":"Quality of life, long-term survivors and long-term outcome from the ABC-02 study","volume":"114","author":"Bridgewater","year":"2016","journal-title":"Br J Cancer"},{"issue":"9","key":"2019062108001609200_djz071-B13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","article-title":"Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study","volume":"15","author":"Andre","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"2019062108001609200_djz071-B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000365781","article-title":"Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"60","author":"Eckel","year":"2014","journal-title":"Chemotherapy"},{"issue":"2","key":"2019062108001609200_djz071-B15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","article-title":"Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer","volume":"22","author":"Tsavaris","year":"2004","journal-title":"Invest New Drugs"},{"issue":"3","key":"2019062108001609200_djz071-B16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000011961","article-title":"Two consecutive phase II studies of 5-fluorouracil\/leucovorin\/mitomycin C and of gemcitabine in patients with advanced biliary cancer","volume":"56","author":"Raderer","year":"1999","journal-title":"Oncology"},{"issue":"12","key":"2019062108001609200_djz071-B17","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"2019062108001609200_djz071-B18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","article-title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study","volume":"49","author":"Walter","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"2019062108001609200_djz071-B19","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","article-title":"Outcome of second-line chemotherapy for biliary tract cancer","volume":"49","author":"Bridgewater","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"2019062108001609200_djz071-B20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s10637-010-9417-3","article-title":"Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness","volume":"29","author":"Oh","year":"2011","journal-title":"Invest New Drugs"},{"issue":"4","key":"2019062108001609200_djz071-B21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/COC.0b013e31818c08ff","article-title":"Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer","volume":"32","author":"Lee","year":"2009","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2019062108001609200_djz071-B22","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","article-title":"Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine","volume":"30","author":"Sasaki","year":"2012","journal-title":"Invest New Drugs"},{"issue":"4","key":"2019062108001609200_djz071-B23","first-page":"IV252.","article-title":"ABC-06: a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin\/5-FU chemotherapy for patients with locally advanced\/metastatic biliary tract cancer (ABC) previously treated with cisplatin\/gemcitabine chemotherapy. ESMO Meeting, 748TiP","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"issue":"10","key":"2019062108001609200_djz071-B24","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.humpath.2011.12.007","article-title":"Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma","volume":"43","author":"Kipp","year":"2012","journal-title":"Hum Pathol"},{"issue":"25","key":"2019062108001609200_djz071-B25","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"2019062108001609200_djz071-B26","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2019062108001609200_djz071-B27","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"2019062108001609200_djz071-B28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.2015-0210","article-title":"Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma","volume":"20","author":"Goyal","year":"2015","journal-title":"Oncologist"},{"issue":"15","key":"2019062108001609200_djz071-B29","doi-asserted-by":"crossref","first-page":"4015.","DOI":"10.1200\/JCO.2017.35.15_suppl.4015","article-title":"Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts","volume":"35","author":"Lowery","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019062108001609200_djz071-B30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"4","key":"2019062108001609200_djz071-B31","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"2019062108001609200_djz071-B32","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"issue":"12","key":"2019062108001609200_djz071-B33","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"2019062108001609200_djz071-B34","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"issue":"2","key":"2019062108001609200_djz071-B35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"4S","key":"2019062108001609200_djz071-B36","first-page":"abstr 335","article-title":"A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. 2016 Gastrointestinal Cancers Symposium","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"2019062108001609200_djz071-B37","year":"2016"},{"issue":"12","key":"2019062108001609200_djz071-B38","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","article-title":"Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis","volume":"20","author":"Hyder","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2019062108001609200_djz071-B39","author":"NCCN (National Comprehensive Cancer Network","year":"2015"},{"issue":"1","key":"2019062108001609200_djz071-B40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2019062108001609200_djz071-B41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.RVI.0000143768.60751.78","article-title":"Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution","volume":"16","author":"Burger","year":"2005","journal-title":"J Vasc Interv Radiol"},{"issue":"8","key":"2019062108001609200_djz071-B42","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23818","article-title":"Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study","volume":"113","author":"Ibrahim","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"2019062108001609200_djz071-B43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2011.07.012","article-title":"Radioembolization for hepatocellular carcinoma","volume":"56","author":"Sangro","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"2019062108001609200_djz071-B44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s12149-015-1026-y","article-title":"Radioembolization with (90)Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors","volume":"30","author":"Soydal","year":"2016","journal-title":"Ann Nucl Med"},{"key":"2019062108001609200_djz071-B45","year":"2017"},{"issue":"12","key":"2019062108001609200_djz071-B46","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-016-0424-4","article-title":"Chemosaturation percutaneous hepatic perfusion: a systematic review","volume":"33","author":"Vogel","year":"2016","journal-title":"Adv Ther"},{"issue":"10","key":"2019062108001609200_djz071-B47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","article-title":"Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors","volume":"143","author":"Kirstein","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"2019062108001609200_djz071-B48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study\u2014The UK ABC-01 study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"issue":"8","key":"2019062108001609200_djz071-B49","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019062108001609200_djz071-B50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2019062108001609200_djz071-B51","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"2019062108001609200_djz071-B52","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1054\/bjoc.2000.1757","article-title":"SOR: project methodology","volume":"84","author":"Fervers","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"2019062108001609200_djz071-B53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrgastro.2011.20","article-title":"Cholangiocarcinoma\u2014controversies and challenges","volume":"8","author":"Patel","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019062108001609200_djz071-B54","doi-asserted-by":"crossref","first-page":"b5087.","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"Levesque","year":"2010","journal-title":"BMJ"},{"issue":"8","key":"2019062108001609200_djz071-B55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jvir.2013.02.031","article-title":"Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis","volume":"24","author":"Mouli","year":"2013","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"2019062108001609200_djz071-B56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival","volume":"35","author":"Hoffmann","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"2019062108001609200_djz071-B57","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2019062108001609200_djz071-B58","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","article-title":"Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study","volume":"36","author":"Rafi","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"8","key":"2019062108001609200_djz071-B59","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jvir.2018.04.001","article-title":"Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study","volume":"29","author":"Gangi","year":"2018","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"2019062108001609200_djz071-B60","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/RLU.0000000000000904","article-title":"Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma","volume":"40","author":"Edeline","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2019062108001609200_djz071-B61","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/annonc\/mdv483","article-title":"Prognostic factors for progression-free and overall survival in advanced biliary tract cancer","volume":"27","author":"Bridgewater","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"2019062108001609200_djz071-B62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11912-017-0603-8","article-title":"Update on treatment options for advanced bile duct tumours: radioembolisation for advanced cholangiocarcinoma","volume":"19","author":"Najran","year":"2017","journal-title":"Curr Oncol Rep"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djz071\/28852013\/djz071.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T14:41:35Z","timestamp":1569163295000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djz071\/5488118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":62,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz071","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,11]]},"article-number":"djz071"}}